Browse Topic
Stem Cells
-
September 13, 2023Record external funding supports UC Davis School of Medicine research
UC Davis exceeded $1 billion in external research funding in the fiscal year 2022–23. The School of Medicine contributed 40% of this amount, achieving a new research funding record.
Read More
-
June 07, 2023UC Davis and Orgenesis partner to boost access to gene and cell therapies in California
UC Davis and Orgenesis are rolling out processing units that allow cell and gene therapies to be developed and manufactured onsite. This will increase patient access to therapies.
Read More
-
April 18, 2023
UC Davis Health receives 2023 Top Ten Clinical Research Achievement Award
Chair of Physical Medicine and Rehabilitation Craig McDonald was honored with a 2023 Top Ten Clinical Research Achievement Award, in recognition of his remarkable work on Duchenne muscular dystrophy.
Read More
-
February 28, 2023Clinical trial for patients with swallowing difficulties after cancer treatment
Researchers have begun a new stem cell clinical trial to treat patients with swallowing problems. The study takes stem cells and injects them into the patient’s tongue.
Read More -
February 21, 2023UC Davis Health to develop in-utero therapy for Duchenne muscular dystrophy
Professor Aijun Wang won a $2 million grant from California’s Stem Cell Agency to develop a cure to Duchenne muscular dystrophy (DMD) using an in-utero gene editing formula.
Read More
-
December 27, 2022UC Davis partners with Caring Cross and CIRM to develop immunotherapy for cancer patients
Immunologist William Murphy discusses CAR T-cell cancer therapy and his work with Caring Cross, CIRM and UC Davis researchers to find novel cures to leukemia and lymphoma.
Read More -
December 14, 2022UC Davis Alpha Stem Cell Clinic receives $8 million from California’s stem cell agency
CIRM awarded UC Davis’ Alpha Stem Cell Clinic an $8 million grant renewal to expand its successful clinical trials operation and advance toward onsite manufacturing of therapies.
Read More
-
October 11, 2022CuRe trial gives hope to new mom
Michelle and Jeff were excited to build their new family together, but when she received the distressing news that her developing baby was diagnosed with spina bifida, she looked for the best treatment. She was referred to the CuRe trial.
Read More -
October 06, 2022
World’s first stem cell treatment for spina bifida delivered during fetal surgery
Three babies have been born after receiving the world’s first spina bifida treatment combining surgery with stem cells. This was made possible by a landmark clinical trial at UC Davis Health known formally as the “CuRe Trial: Cellular Therapy for In Utero Repair of Myelomeningocele.”
Read More
-
August 22, 2022Surgery resident awarded prestigious T32 federal research grant
Cardiothoracic surgery resident Nataliya Bahatyrevich has become the latest UC Davis trainee to receive a prestigious T32 federal research grant. The award will allow her to spend a year in the laboratory and pursue a Master of Science in biomedical engineering at UC Davis
Read More
-
June 17, 2022Jan Nolta receives 2022 Chancellor’s Lifetime Achievement Award in Innovation
Stem cell researcher Jan Nolta received the Lifetime Achievement Award in Innovation during the 2022 Chancellor’s Innovation Awards ceremony on June 16. The awards recognize faculty, community partners and industry leaders developing innovative solutions to improve the lives of others and address important needs in the global society.
Read More
-
May 26, 2022UC Davis wins $3 million CIRM grant to develop smart vascular graft for kidney patients
Professor Aijun Wang won $3 million grant from California Institute for Regenerative Medicine to develop a smart durable vascular device for hemodialysis patients treated for kidney failure. The device uses a unique molecule to help prevent synthetic vascular graft failure, a common problem for patients undergoing hemodialysis.
Read More
-
March 29, 2022$4 million research program seeks therapy for rare genetic condition ADNP syndrome
The UC Davis MIND Institute is launching a $4 million research program aimed at finding transformative therapies for ADNP syndrome, a rare genetic condition. A group of interdisciplinary researchers will evaluate multiple gene therapies for possible use.
Read More -
March 10, 2022Cellular therapy improves signs and symptoms of Duchenne muscular dystrophy
In a first of its kind clinical trial led by UC Davis Health, HOPE-2 showed that cellular therapy is safe and effective in stopping the deterioration of upper limb and heart functions in patients with late-stage Duchenne muscular dystrophy.
Read More
-
December 16, 2021New potential treatment for graft-versus-host-disease and other inflammatory disorders
UC Davis Health researchers showed that blocking IL-6 and TNF cytokines provides a more effective approach to preventing life-threatening graft-versus-host-disease, an inflammatory condition that develops in patients after their allogeneic hematopoietic stem cell transplantation.
Read More
-
September 20, 2021UC President Michael Drake on campus to help induct Eye Center chairholder
UC President Michael Drake was at the UC Davis Health campus to help induct the new presidential chair in vitreoretinal science. The inaugural appointment of world-renowned physician Paul A. Sieving was held Sept. 17 with recognition of Neil and MJ Kelly and their generous donation that established the Kelly Presidential Chair in Vitreoretinal Science.
Read More
-
August 26, 2021California’s stem cell agency funds research into Angelman syndrome and bioprint pacemaker
Professors David Segal and Deborah Lieu have received Discovery Stage Research Projects awards from the California Institute for Regenerative Medicine (CIRM). The grants will fund cell gene therapy for Angelman syndrome and building the first biopacemaker
Read More
-
June 23, 2021Research provides a roadmap to HIV eradication via stem cell therapy
A groundbreaking study found that stem cells reduce the amount of virus causing AIDS, boost the body’s antiviral immunity, and restore the gut’s lymphoid follicles damaged by HIV. It provided a roadmap for multi-pronged HIV eradication strategies.
Read More
-
March 01, 2021First stem cell clinical trial for spina bifida treatment announced
A UC Davis Health team today announced the launch of the world’s first FDA-approved human clinical trial to treat the most serious form of spina bifida. The trial involves the use of stem cells, applied during a surgery before birth.
Read More
-
November 12, 2020State stem cell agency funds clinical trial for spina bifida treatment
California’s stem cell agency awarded funding to UC Davis Health researchers for the first human clinical trial using stem cells to treat spina bifida.
Read More